ESMO 2023 BioNTech Data

7 BNT325/DB-13051 - TROP2 ADC • • The three components of BNT325/DB-13051: • Humanized anti-TROP2 IgG1 mAb Proprietary DNA topoisomerase I inhibitor (P1021) Cleavable linker Y Humanized anti-TROP2 IgG1 mAb Interchain Cysteine Residue Linker-Payload Key Attributes of BNT325/DB-1305 Selectively endocytosed into the lysosome of Trop-2+ cells. Optimized drug-to-antibody ratio: ~4 • Tumor-selective cleavable linker • Stable linker-payload High potency of payload with a short systemic half-life • Payload mechanism of action: topoisomerase I inhibitor • Bystander antitumor effect 1. Partnered with Duality Bio; BIONTECH

View entire presentation